AHRQ: $52.2 billion allocated to prescription medications for treatment of metabolic conditions during 2008 Insurers and customers spent $52.2 billion on prescription medications in 2008 for outpatient treatment of metabolic circumstances such as diabetes and elevated cholesterol, based on the latest News and Quantities from the Agency for Healthcare Research and Quality . Metabolic medicines were the course of medications with the highest degree of spending in 2008. Relating to data from the federal government agency, buys of metabolic medications by adults age 18 and older accounted for 22 % of the nearly $233 billion spent overall to get prescription medicines in 2008.The incidence of febrile neutropenia of quality 3 or more among sufferers from Asia was 12 percent in the control group and 26 percent in the pertuzumab group; in all other geographic regions, the incidence was 10 percent or less in both groups. Left ventricular systolic dysfunction was reported more often in the control group than in the pertuzumab group . Left ventricular systolic dysfunction of grade 3 or more was reported in 2.8 percent of the sufferers in the control group and in 1.2 percent of the individuals in the pertuzumab group. Among patients in whom the still left ventricular ejection fraction was assessed following the baseline assessment, 6.6 percent in the control group and 3.8 percent in the pertuzumab group had declines of 10 %age points or more from baseline that resulted in a left ventricular ejection fraction of less than 50 percent.